| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdd619b8a2cc2f110b9ee4dc8d896a17 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b937dcfa91c0969983da9694d4504edd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b511bfe344a0efabe530289f4de5ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca7f5f5503167afa9a75dbb8cce4760d |
| publicationDate |
2010-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010215667-A |
| titleOfInvention |
Use of β-adrenergic receptor antagonists for the manufacture of a medicament for treating diseases of the outer retina |
| abstract |
A β-adrenergic receptor antagonist useful in treating a disease of the outer retina is provided. The present invention relates to the use of β-adrenergic receptor antagonists for the manufacture of a medicament for treating the following outer retinal diseases: ARMD; RP and other forms of genetically modified retinal diseases; retina Exfoliation and rupture; macular fistula; ischemia affecting the outer retina; damage associated with laser therapy (lattice, focal and wide retina) including photodynamic therapy, heat or cold therapy; trauma; surgical (retinal translocation, retina Subsurgery or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal grafts. [Selection figure] None |
| priorityDate |
1999-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |